Zydus Wellness Stock Surges 10% After Brokerage Slaps 'Buy' Rating, Targets 35% Jump!

CONSUMER-PRODUCTS
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Zydus Wellness Stock Surges 10% After Brokerage Slaps 'Buy' Rating, Targets 35% Jump!
Overview

Zydus Wellness shares surged nearly 10% over two days after Motilal Oswal initiated coverage with a 'Buy' rating and a target price of ₹575, suggesting up to 35% upside. The brokerage highlighted the company's diversified health and nutrition portfolio, including brands like Glucon-D and Complan, and its expansion into high-protein and wellness trends through recent acquisitions. Motilal Oswal believes Zydus Wellness offers a strong risk-reward profile, especially given its potential for superior earnings growth compared to its past performance.

Zydus Wellness Shares Rally on Motilal Oswal's 'Buy' Call

Zydus Wellness shares experienced a significant rally, jumping nearly 10% in just two trading sessions. This surge was primarily triggered by a strong 'Buy' recommendation and a high target price set by leading domestic brokerage firm Motilal Oswal. The brokerage initiated coverage on the stock, signalling substantial upside potential for investors.

The optimistic outlook from Motilal Oswal propelled Zydus Wellness shares to an intraday high of ₹483.40 on Thursday, before settling around 2% higher at ₹465.50. This performance follows a broader upward trend over the past week, indicating renewed investor interest following the bullish report.

Motilal Oswal's Bullish Stance

Motilal Oswal's analysis, released on December 31, established a target price of ₹575 per share for Zydus Wellness. This target implies a potential appreciation of approximately 35% from the stock's closing price of ₹424 on December 30. The brokerage firm lauded Zydus Wellness as a diversified health and nutrition company with a leading position in multiple consumer wellness categories.

The firm highlighted Zydus Wellness's robust core portfolio, which includes well-known brands such as Sugar Free, Glucon-D, Everyuth, Nutralite, Complan, and Nycil. Motilal Oswal emphasized that the company consistently maintains dominant market positions across these essential categories.

Strategic Expansion and Market Trends

The brokerage further noted that recent strategic acquisitions, such as Naturell (which owns RiteBite Max Protein) and Comfort Click (covering a VMS portfolio), have been instrumental in expanding Zydus Wellness's footprint. These moves strategically position the company to capitalize on burgeoning consumer trends like high-protein snacks, preventive health solutions, and digitally-driven nutrition services.

Motilal Oswal pointed out that Zydus Wellness's product range is well-aligned with global megatrends. These include the increasing demand for low/no-sugar options, high-protein products, preventive wellness, and convenient functional nutrition. Unlike many Fast-Moving Consumer Goods (FMCG) peers facing user-addition challenges in core segments, Zydus is poised to expand its user base, particularly among younger demographics and affluent consumers.

Valuation and Future Growth

The firm sees Zydus Wellness as having one of the most attractive risk-reward profiles among its peers within a similar market capitalization range. Despite past earnings growth that was moderate (7-8% CAGR over a decade), Motilal Oswal anticipates significantly superior performance ahead. This optimism stems from the stabilization of its core portfolio and the promising growth avenues presented by its newer ventures.

Motilal Oswal projects an organic EBITDA CAGR of 14% and a consolidated EBITDA CAGR of 36% for Zydus Wellness between fiscal years 2025 and 2028. Currently trading at 22x P/E and 16x EV/EBITDA for FY28 estimates, the stock is priced at a 30-35% discount compared to other FMCG companies. This valuation makes it the most compelling investment opportunity in the consumer segment for companies with a market cap under ₹15,000 crore.

Impact

This 'Buy' rating and target price revision by Motilal Oswal are likely to sustain positive investor sentiment for Zydus Wellness shares. It may attract further institutional interest and potentially lead to increased trading volumes. For existing shareholders, it validates their investment and offers a clear path to potential capital appreciation. The news also highlights the growing investor focus on health and wellness segments within the Indian consumer market.
Impact Rating: 7/10

Difficult Terms Explained

  • Initiated Coverage: A financial analyst or brokerage firm beginning to research and provide recommendations on a specific stock.
  • Upside Potential: The projected increase in a stock's price based on an analyst's target price, indicating how much more the stock is expected to gain.
  • Diversified: Offering a range of products or services across different categories to reduce risk and capture multiple market segments.
  • CAGR: Compound Annual Growth Rate, a measure of average annual growth over a specified period, assuming profits were reinvested.
  • EBITDA: Earnings Before Interest, Taxes, Depreciation, and Amortization; a measure of a company's operating performance.
  • P/E: Price-to-Earnings ratio, a valuation metric comparing a company's share price to its earnings per share.
  • EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization ratio, another valuation metric often used to compare companies within the same industry.
  • FMCG: Fast-Moving Consumer Goods, products that are sold quickly and at a relatively low cost, such as packaged foods, drinks, toiletries, and over-the-counter drugs.
  • Market Capitalization: The total value of a company's outstanding shares of stock.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.